| __timestamp | Neurocrine Biosciences, Inc. | TG Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 24518692 |
| Thursday, January 1, 2015 | 32480000 | 19886580 |
| Friday, January 1, 2016 | 68081000 | 12631689 |
| Sunday, January 1, 2017 | 169906000 | 21977998 |
| Monday, January 1, 2018 | 248932000 | 20759000 |
| Tuesday, January 1, 2019 | 354100000 | 20838000 |
| Wednesday, January 1, 2020 | 433300000 | 121812000 |
| Friday, January 1, 2021 | 583300000 | 152137000 |
| Saturday, January 1, 2022 | 752700000 | 83231000 |
| Sunday, January 1, 2023 | 887600000 | 122706000 |
| Monday, January 1, 2024 | 1007200000 |
In pursuit of knowledge
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Neurocrine Biosciences, Inc. and TG Therapeutics, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Neurocrine Biosciences has seen a staggering increase of nearly 4,800% in SG&A expenses from 2014 to 2023, reflecting its aggressive expansion and operational scaling. In contrast, TG Therapeutics, while also experiencing growth, has maintained a more conservative increase of approximately 400% over the same period.
This divergence highlights the strategic differences between the two companies. Neurocrine's substantial investment in operational costs suggests a focus on rapid growth and market penetration, whereas TG Therapeutics appears to be adopting a more measured approach. As the biotech sector continues to grow, these strategies will undoubtedly shape the future trajectories of these companies.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Novartis AG and Neurocrine Biosciences, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs TG Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and TG Therapeutics, Inc.
United Therapeutics Corporation and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Incyte Corporation Trends and Insights
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Celldex Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alkermes plc and TG Therapeutics, Inc.
Opthea Limited vs TG Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and Perrigo Company plc
Comparing SG&A Expenses: TG Therapeutics, Inc. vs Dynavax Technologies Corporation Trends and Insights